<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-carvedilol.xml</id>
  <title>Recalls Watch: Carvedilol</title>
  <link rel="self" href="https://recalls.watch/feed/substance-carvedilol.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2025-08-27T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/97449/</id>
    <title>The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories: Carvedilol Tablets USP</title>
    <link href="https://recalls.watch/recall/fda/97449/"/>
    <updated>2025-08-27T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97372/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more</title>
    <link href="https://recalls.watch/recall/fda/97372/"/>
    <updated>2025-08-20T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97370/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 2 more</title>
    <link href="https://recalls.watch/recall/fda/97370/"/>
    <updated>2025-08-20T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96861/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets USP 3.125mg Tablets a.)100-count bottle and 3 more</title>
    <link href="https://recalls.watch/recall/fda/96861/"/>
    <updated>2025-06-04T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations; presence 'N-Nitroso Carvedilol I' Impurity above the recommended acceptable intake limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96474/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Fenofibrate Capsules 67 mg and 38 more</title>
    <link href="https://recalls.watch/recall/fda/96474/"/>
    <updated>2025-04-16T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96191/</id>
    <title>RemedyRepack Inc.: Carvedilol 25 mg Tablet</title>
    <link href="https://recalls.watch/recall/fda/96191/"/>
    <updated>2025-02-12T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP deviations: presence of N-Nitroso Carvedilol Impurity-1 (NNC 1), above the FDA recommended acceptable intake limit.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96162/</id>
    <title>Glenmark Pharmaceuticals Inc., USA: Carvedilol Tablets and 1 more</title>
    <link href="https://recalls.watch/recall/fda/96162/"/>
    <updated>2025-02-12T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.</summary>
  </entry>
</feed>
